POH
Click for more information
0.00% 0.0¢ progress 2023-2 trust

Ann: FDA meeting provides guidance for TPM/Oxymorphone patch, page-30

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW
TRADE NOW
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW
  1. hottod
    3,464 Posts.
    lightbulb Created with Sketch. 2300
    clock Created with Sketch.
    19/01/19
    17:11
    Post #: 37164899
    Turps, not that long a shot….

    There’s been a notable shift by pharma in the past few years towards licensing earlier-stage assets. In 2017, pre-clinical and Phase 1 assets accounted for just under 60% of total pharma licensing deals.

    https://resultshealthcare.com/insight/licensing-cornerstone-biotech-value-creation/

    https://blog.lifesciencenation.com/...als-global-pharmas-looking-earlier-than-ever/
    POH Price at posting: 0.5¢ Sentiment: Hold Disclosure: Held
    Likes Created with Sketch. 11  Upvote
    lightbulb Created with Sketch. 3  Great analysis
    Stroke 3 Created with Sketch. Comments Created with Sketch. Reply

  2. Top Stories

 
watchlist Created with Sketch. Add POH (ASX) to my watchlist
(20min delay)
Last
0.0¢ 		Change
0.000(0.00%) 		Mkt cap ! n/a
Open High Low Value Volume
0.0¢ 0.0¢ 0.0¢ $0 0
POH (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.